XTL Biopharmaceuticals
XTLB
4 hedge funds and large institutions have $299K invested in XTL Biopharmaceuticals in 2025 Q1 according to their latest regulatory filings, with 1 funds opening new positions, 0 increasing their positions, 1 reducing their positions, and closing their positions.
33% more funds holding
Funds holding: 3 → 4 (+1)
0% more ownership
Funds ownership: 0% → 0% (+0%)
35% less capital invested
Capital invested by funds: $463K → $299K (-$164K)
100% less repeat investments, than reductions
Existing positions increased: 0 | Existing positions reduced: 1
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
+$38.6K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
-$7.81K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
NI
1
Noked Israel
Ramat Hasharon,
Israel
| $238K | – | – | – |
|
|
2
Citadel Advisors
Miami,
Florida
| $31.3K | +$38.6K | +6,303 | New |
|
|
3
Morgan Stanley
New York
| $15.8K | -$7.81K | -1,275 | -28% |
|
4
RhumbLine Advisers
Boston,
Massachusetts
| $13.6K | – | – | – |
|
XTLB Hedge Fund Activity: Q1 2025 in Review
4 of the 7,464 institutional investors tracked by Wall St. Rank reported a position in XTL Biopharmaceuticals (XTLB) for Q1 2025, worth a combined $299K — down 35% from $463K a quarter earlier.
Buyers outnumbered sellers: 1 fund opened new XTLB positions and 0 closed out — a net gain of 1 holder — while 0 added to existing stakes and 1 trimmed.
The largest buyer was Citadel Advisors, opening a new position worth an estimated $38.6K. The largest seller was Morgan Stanley, cutting an estimated $7.81K.
- 4 institutional investors held XTL Biopharmaceuticals (XTLB) as of Q1 2025, up from 3 in Q4 2024.
- Funds reported $299K of XTL Biopharmaceuticals stock for Q1 2025, down 35% quarter-over-quarter.
- 1 fund opened new XTL Biopharmaceuticals positions in Q1 2025 and 0 closed out, a net change of +1 holder.
- The largest XTL Biopharmaceuticals buyer in Q1 2025 was Citadel Advisors, an estimated $38.6K added.
- The largest XTL Biopharmaceuticals seller in Q1 2025 was Morgan Stanley, an estimated $7.81K sold.
Based on aggregated 13F filings for Q1 2025.